Rosen Announces More Medications Qualify for Medicare Price Negotiations

15 Additional Medications Will Be Eligible To Have Their Prices Lowered
WASHINGTON, DC– Today, U.S. Senator Jacky Rosen (D-NV) announced that 15 additional medications have been selected for Medicare drug pricing negotiations, which will lower their costs for seniors on Medicare Part D. Thanks to theInflation Reduction Actthat Senator Rosen helped pass, Medicare now has the authority to negotiate prescription drug prices directly with pharmaceutical companies. These 15 new drugs are in addition to the ten prescription drugs that have already been negotiated under this authority, with lowered prices set to go into effect in 2026. The new drugs selected for price negotiations include:
“Nevadans are being squeezed by rising costs, and I’ve been fighting to lower them, including prescription drug prices”said Senator Rosen.“I’m proud to announce that thanks to legislation I helped pass, 15 additional medications will qualify for Medicare price negotiations, which will help lower their prices and provide relief for our seniors.”
Senator Rosen has been leading the fight to lower prescription drug costs. Thanks to theInflation Reduction Act, Senator Rosen helped lower prescription drug costs for seniors, lower health care premiums, and cap the insulin costs for those on Medicare Part D at $35/month per prescription. Last year, she joined anamicus briefsupporting that federal law. Senator Rosen also introducedbipartisan legislationto lower out-of-pocket prescription drug costs for seniors. Last year, sheannouncedthat Nevada seniors would have their annual out-of-pocket costs for brand-name prescription drugs effectively capped at $3,300 a year as a result of the legislation she helped pass.
###